ORITAVANCIN DIPHOSPHATE
| Brand name | ORBACTIV |
|---|---|
| Active ingredient | ORITAVANCIN DIPHOSPHATE |
| Strength | EQ 400MG BASE/VIAL |
| Dosage form | POWDER |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | August 2014 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9649352 | July 2035 | product |
| 9682061 | April 2030 | use U-1569 |
| 8420592 | August 2029 | use U-1570 |
| 12514899 | August 2029 | use U-4398 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.